ムコ多糖類の世界市場 (2025年～2033年)

ムコ多糖類の世界市場は、2024年に23億1,308万米ドルに達し、2033年には43億8,985万米ドルに達すると予測され、予測期間2025-2033年のCAGRは7.5%で成長すると予測されています。ムコ多糖類は、グリコサミノグリカンの分解を触媒する酵素の遺伝子変異によって引き起こされる遺伝性のリソソーム貯蔵疾患群です。グリコサミノグリカンはムコ多糖類としても知られ、細胞シグナル伝達、骨、結合組織、角膜の成長と開発に重要な役割を果たす炭水化物分子です。これらのグリコサミノグリカンは11種類の酵素によって分解されますが、その酵素が変異すると、その機能が不適切になったり、失われたりします。その結果、グリコサミノグリカンは血液、脳、脊髄、結合組織に蓄積し、身体的形態異常から認知障害に至るまで様々な症状を引き起こします。

市場力学：

促進要因と抑制要因

新規製品の承認と開発活動の増加

ムコ多糖類は、アンメットニーズの高い疾患群です。現在の研究開発は、疾患修飾療法を開発し、その後市場に投入することに焦点が当てられています。最近、ムコ多糖症の治療情勢は、世界中の規制当局からいくつかの治療薬が販売許可を取得したことにより、牽引役となっています。さらに、いくつかのパイプライン医薬品は、承認プロセスを迅速化し、早期の市場参入を可能にする臨床マイルストーンや特別指定を受けています。予測期間には、サンフィリッポ症候群のようなアンメットニーズの高いムコ多糖症の市場参入が期待されています。

例えば、2025年2月5日、Ultragenyx Pharmaceutical Inc.は、サンフィリッポ症候群A型（MPS IIIA）患者の治療を目的とした新規AAVベース遺伝子治療薬UX111の良好な臨床試験データを報告しました。臨床試験の結果、UX111は治療した患者の認知能力と受容的・表現的コミュニケーションを有意に改善したことが示されました。これは、サンフィリポ治療における重要なマイルストーンとなります。2025年2月18日、ウルトラジェニックスは、米国FDAがUX111の生物製剤承認申請（BLA）を受理し、優先審査の対象として検討されていることを発表しました。ウルトラジェニックス社は早期承認を求めており、2025年8月18日までに決定される予定です。ウルトラジェニックス社が承認されれば、同社はこの画期的な治療薬を商業的に市場に投入する準備が整うことになります。

このようなパイプラインの医薬品は臨床試験で良好な成績を収めており、規制当局の承認を目前にしているものがいくつかあります。これらの医薬品が承認されれば、ムコ多糖類の治療状況に革命をもたらすと期待されています。

以下は、ムコ多糖類のタイプ別に、様々な臨床段階にある主要パイプライン医薬品の一覧です。

承認薬の高コストが市場成長を抑制する可能性。

酵素補充療法（ERT）はMPSの現在の標準治療ですが、患者は長期間の治療が必要となります。これは、適切な保険に加入しておらず、保険会社が定める厳しい規則を満たさない患者にとっては、経済的に大きな負担となり得ます。さらに、予測期間中にはいくつかの疾患修飾療法が市場参入すると予想されます。これらの治療法は、現在の標準治療であるERTと比較して高価格になることが予想されます。そのため、アンメットニーズは高いもの、採用率の妨げになる可能性があります。

目次

第1章 分析手法・範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • MPS患者の診断率・治療率が上昇
    • 新規製品の承認増加
  • 抑制要因
    • 承認済み医薬品の入手制約
    • 患者のコンプライアンス問題
  • 市場機会
    • 新興国におけるアクセスの拡大
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学
• 価格分析
• パイプライン分析
• 特許分析
• 規制分析

第6章 種類別

• MPS I（ハーラー症候群）
• MPS II（ハンター症候群）
• MPS IV（モルキオ症候群）
• MPS VI（マロー・ラミー症候群）
• MPS VII（スライ症候群）
• その他

第7章 薬剤別

• ラロニダーゼ
• イデュルスルファーゼ
• パビナフスプアルファ
• エロスルファーゼアルファ
• ガルスルファーゼ
• ヴェストロニダーゼアルファ-vjbk
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Sanofi
  • 会社概要
  • 製品ポートフォリオ
    • 製品概要
    • 製品の主要業績評価指標（KPI）
    • 製品販売の実績・予測
    • 製品販売量
  • 財務概要
    • 企業の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 企業合併・買収 (M&A)
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Takeda Pharmaceuticals
• GC Biopharma corporate.
• CANbridge Life Sciences Ltd.
• JCR Pharmaceuticals Co., Ltd.
• BioMarin Pharmaceutical Inc.
• Ultragenyx Pharmaceutical Inc.
• Orchard Therapeutics plc
• REGENXBIO Inc.
• NS Pharma, Inc.
• Generium
• ESTEVE
• Inventiva.
• Allievex Corporation
• Paradigm Biopharmaceuticals Ltd.
• Denali Therapeutics
• IMMUSOFT
• 各市場参入企業に対しても同様のデータが提供されます。

第11章 付録

The global Mucopolysaccharidoses market reached US$ 2,313.08 million in 2024 and is expected to reach US$ 4,389.85 million by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033. Mucopolysaccharidoses are a group of inherited lysosomal storage diseases caused by genetic mutations in the enzymes that catalyze glycosaminoglycans breakdown. Glycosaminoglycans, also known as mucopolysaccharides, are the carbohydrate molecules that play a crucial role in cell signaling, growth & development of bones, connective tissues, and corneas. These glycosaminoglycans are broken down by 11 different types of enzymes, whose mutation leads to improper or loss of their function. As a result, the glycosaminoglycans accumulate in the blood, brain, spinal cord, and connective tissue, leading to a variety of symptoms ranging from physical dysmorphia to cognitive impairment.

Market Dynamics: Drivers & Restraints

Rising Novel Product Approvals and Development Activities

Mucopolysaccharidoses are a group of conditions with high unmet needs. The current research efforts were focused on developing disease-modifying therapies and subsequently launching them into the market. In recent times, the mucopolysaccharidosis treatment landscape has seen traction due to the marketing authorization of several therapies provided by regulatory bodies across the world. Moreover, several pipeline drugs have received clinical milestones and special designations that can expedite their approval process and gain early market access. In the forecast period, several pipeline products are expected to make market entry for some mucopolysaccharidose conditions with high unmet needs, such as Sanfilippo syndrome.

For instance, on February 5, 2025, Ultragenyx Pharmaceutical Inc. reported positive clinical trial data for its novel AAV-based gene therapy UX111, which is aimed at the treatment of patients with Sanfilippo syndrome type A (MPS IIIA). The clinical results showed that UX111 has significantly improved cognitive ability and receptive & expressive communication in treated patients. This is a significant milestone in the Sanfilippo treatment landscape. On February 18, 2025, Ultragenyx announced that the U.S. FDA accepted the Biologics License Application (BLA) of UX111, and it is being considered for priority review. Ultragenyx is seeking accelerated approval, and the decision is expected by August 18, 2025. Once Ultragenyx receives a positive nod, the company will be ready to launch this revolutionary therapy commercially into the market.

Several such pipeline drugs are performing well in clinical trials and are on the verge of regulatory approval. Once these drugs are approved, they are expected to revolutionize the mucopolysaccharidoses treatment landscape.

Below is the representation of key pipeline drugs that are in various clinical phases for different types of mucopolysaccharidoses.

High- Cost of Approved Drugs May Restrain the Market Growth.

Enzyme replacement therapies (ERTs) are the current standard of treatment for MPS, however, patients need to be on long-term therapy. This can be a significant economic burden to the patient who does not have proper insurance coverage and does not meet the stringent rules put forth by the insurance companies. Moreover, several disease-modifying therapies are expected to make market entry in the forecast period. These therapies are expected to have higher prices as compared to the current standard of care ERTs. This can hinder the adoption rate, although the unmet needs are high.

Segment Analysis

The global Mucopolysaccharidoses market is segmented based on type, drug, and region.

Elosulfase Alfa in the drug segment is dominating the market.

Elosulfase Alfa, sold under the brand name VIMIZIM, manufactured by BioMarin Pharmaceutical Inc. is an enzyme replacement therapy indicated for the treatment of Mucopolysaccharidosis type IVA, also known as Morquio A syndrome. The drug first received marketing authorization in the U.S. in February 2014, followed by EU marketing authorization in April 2014 and Japanese approval in December 2014. Elosulfulase alfa is the first-in-therapy drug for MPS IVA, and no drug has ever been approved since then for the indication. Currently, this drug is the top-selling one in the mucopolysaccharidoses treatment landscape. In 2023, BioMarin reported US$ 701 million in revenue for VIMIZIM, and dataM estimates a revenue of approximately US$ 732 million in 2024. The drug had approximately 32% market share in 2024.

Geographical Analysis

North America dominated the Mucopolysaccharidoses market.

The North America region has the highest market share in the global mucopolysaccharidoses market. The factors contributing to the region's dominance include high diagnosis and treatment rates, first availability of approved drugs,

The patient population in the region, especially in the U.S., is highly aware of their disease and their therapeutic choices. Several non-profit organizations in the U.S. create awareness about the disease, which is the major contributing factor to the high diagnosis and treatment rate. For instance, the National MPS Society is an NGO in the U.S. that supports scientific research, family support, and public awareness of MPS disorders. They raise funds, sponsor events, and advocate for support programs, offering resource guides, emotional forums, and family conferences. Several such organizations that are advocating for MPS patients include The National Organization for Rare Disorders (NORD), Project Alive, Angel's Hands Foundation, etc. All these organizations are contributing to the improved diagnosis rate of rare diseases like mucopolysaccharidoses.

In addition to the higher diagnosis rate, the percentage of the population receiving treatment is also high. This is due to the availability of disease-modifying therapies at the patient's convenience. 5 out of seven approved therapies, such as Aldurazyme, Elaprase, VIMIZIM, Naglazyme, and Mepsevii, are available in the region. This represents the region's higher demand for disease-modifying therapies and how manufacturers favor the region first for their product launch.

In addition to these factors, the high sales generated by market players and the robust clinical pipeline are major factors contributing to the region's dominance.

Competitive Landscape

The major players in the Mucopolysaccharidoses market are Sanofi, Takeda Pharmaceuticals, GC Biopharma Corporate., JCR Pharmaceuticals Co., Ltd., BioMarin Pharmaceutical Inc., and Ultragenyx Pharmaceutical Inc., among others.

Key Developments

• On February 18, 2025, Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for UX111, an AAV vector-based gene therapy that is being evaluated for the treatment of Sanfilippo Syndrome Type A (MPS IIIA).
• On January 14, 2025, REGENXBIO Inc. announced a partnership with Nippon Shinyaku Co., Ltd. for the development and commercialization of RGX-121 & RGX-111, two novel gene therapies designated for the treatment of Hunter syndrome (MPS II) and Hurler syndrome (MPS I). REGENXBIO will receive US$ 110 million in payment upon deal closure and an additional US$ 700 million for meeting milestones in the future.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming pharmaceutical advancements.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global melanoma therapeutics market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Diagnosis and Treatment Rate among Patients with MPS
    • 4.1.1.2. Rising Novel Product Approvals
  • 4.1.2. Restraints
    • 4.1.2.1. Limited availability of approved drugs
    • 4.1.2.2. Patient compliance issues
  • 4.1.3. Opportunities
    • 4.1.3.1. Rising Access in Emerging Countries
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiology
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Patent Analysis
• 5.6. Regulatory Analysis

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. MPS I (Hurler Syndrome)*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. MPS II (Hunter Syndrome)
• 6.4. MPS IV (Morquio Syndrome)
• 6.5. MPS VI (Maroteaux-Lamy Syndrome)
• 6.6. MPS VII (Sly Syndrome)
• 6.7. Others

7. By Drug

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 7.1.2. Market Attractiveness Index, By Drug
• 7.2. Laronidase*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Idursulfase
• 7.4. Pabinafusp Alfa
• 7.5. Elosulfase Alfa
• 7.6. Galsulfase
• 7.7. Vestronidase Alfa-vjbk
• 7.8. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

Key Market Players

• 10.1. Sanofi*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue's
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals, etc.
  • 10.1.5. SWOT Analysis
• 10.2. Takeda Pharmaceuticals
• 10.3. GC Biopharma corporate.
• 10.4. CANbridge Life Sciences Ltd.
• 10.5. JCR Pharmaceuticals Co., Ltd.
• 10.6. BioMarin Pharmaceutical Inc.
• 10.7. Ultragenyx Pharmaceutical Inc.

Emerging Market Players

• 10.8. Orchard Therapeutics plc
• 10.9. REGENXBIO Inc.
• 10.10. NS Pharma, Inc.
• 10.11. Generium
• 10.12. ESTEVE
• 10.13. Inventiva.
• 10.14. Allievex Corporation
• 10.15. Paradigm Biopharmaceuticals Ltd.
• 10.16. Denali Therapeutics
• 10.17. IMMUSOFT
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us